Diquafosol Tetrasodium: Tatalaksana Terkini untuk Dry Eye Disease (DED)?
DOI:
https://doi.org/10.55175/cdk.v47i7.604Kata Kunci:
DED, diquafosol tetrasodium, dry eye disease, keratokonjungtivitis siccaAbstrak
Keratokonjungtivitis sicca (dry eye disease/DED) adalah penyakit multifaktorial permukaan okuler yang ditandai dengan hilangnya homeostasis lapisan air mata disertai gejala okuler. Diagnosis dan tatalaksana DED terbatas serta tidak memuaskan. Diquafosol tetrasodium “diquafosol” merupakan agonis reseptor P2Y2 yang dapat digunakan untuk mengobati DED dengan cara merehidrasi permukaan okuler.
Keratoconjunctivitis sicca (dry eye disease/DED) is a multifactorial disease of the ocular surface characterized by loss of tear film homeostasis accompanied by ocular symptoms. Diagnosis and treatment of DED is limited, and the result is not promising. Diquafosol tetrasodium “diquafosol” is a P2Y2 receptor agonist that can be used for DED treatment by rehydrating the ocular surface.
Unduhan
Referensi
Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. TFOS DEWS II report executive summary, the ocular surface. 2017. http://dx.doi.org/10.1016/j.jtos.2017.08.003
Lau OCF, Samarawickrama C, Skalicky SE. P2Y2 receptor agonists for the treatment of dry eye disease: A review. Clin Ophthalmol. 2014;8:327-34.
Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea. 2004;23:784-92.
Kamiya K, Nakanishi M, Ishii R, Kobashi H, Igarashi A, Sato N, et al. Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: A prospective, randomized, multicenter study. Eye. 2012;26:1363-8.
Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II definition and classification report. Ocular Surf. 2017. http://dx.doi.org/10.1016/j.jtos.2017.05.008
Doughty MJ. Fluorescein-tear breakup time as an assessment of efficacy of tear replacement therapy in dry eye patients: A systematic review and meta-analysis. Ocul Surf. 2014;12:100-11. doi:10.1016/j.jtos.2013.11.002.
Doughty MJ, Glavin S. Efficacy of different dry eye treatments with artificial tears or ocular lubricants: A systematic review. Ophthalmic Physiol Opt. 2009;29:573-83. doi:10.1111/j.1475-1313.2009.00683.x
Prokopich LC, Bitton E, Caffery B, et al. Screening, diagnosis and management of dry eye disease: practical guidelines for Canadian optometrists. Can J Optometry 2015;76(suppl 1):4-26.
Kymionis GD, Bouzoukis DI, Diakonis VF, Siganos C. Treatment of chronic dry eye: Focus on cyclosporine. Clin Ophthalmol. 2008;2(4):829-36.
Barber L, Pflugfelder S, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005;112:1790–4.
Zhu W, Wu Y, Li G, Wang J, Li X. Efficacy of polyunsaturated fatty acids for dry eye syndrome: A meta-analysis of randomized controlled trials. Nutr Rev. 2014;72:662-71. doi: 10.1111/nure.12145 pmid:25236365
Nichols KK, Yerxa B, Kellerman DJ. Diquafosol tetrasodium: A novel dry eye therapy. Expert Opin Investig Drugs. 2004;13(1):47-54. http://dx.doi.org/10.1517/13543784.13.1.47
Cowlen MS, Zhang VZ, Warnock L, Moyer CF, Peterson WM, Yerxa BR. Localization of ocular P2Y2 receptor gene expression by in situ hybridization. Exp Eye Res. 2003;77(1):77–84.
Jang HL, In SS, Kyoung LK, Sam YY. Effectiveness and optical quality of topical 3.0% diquafosol versus 0.05% cyclosporine A in dry eye patients following cataract surgery. J Ophthalmol. 2016. http://dx.doi.org/10.1155/2016/8150757
Park JH, Moon SH, Kang DH, Um HJ, Kang SS, Kim JY, et al. Diquafosol sodium inhibits apoptosis and inflammation of corneal epithelial cells via activation of Erk1/2 and RSK: In vitro and in vivo dry eye model. Invest Ophthalmol Vis Sci. 2018;59:5108-15. https://doi.org/10.1167/iovs.17-22925
Yokoi N, Sonomura Y, Kato H, Komura A, Kinoshita S. Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren’s syndrome. Eye. 2015;29:1204-12.
Nagahara Y, Koh S, Nishida K, Watanabe H. Prolonged increase in tear meniscus height by 3% diquafosol ophthalmic solution in eyes with contact lenses. Clin Ophthalmol. 2015;9:1029-31.
Mun Y, Kwon JW, & Oh JY. Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease. BMC Ophthalmol. 2018;18,237. https://doi.org/10.1186/s12886-018-0910-3
Mori Y, Nejima R, Masuda A, Maruyama Y, Minami K, Miyata K, et al. Effect of diquafosol tetrasodium eye drop for persistent dry eye after laser in situ keratomileusis. Cornea. 2014;33(7), 659–662. doi:10.1097/ico.0000000000000136
Nakamura M, Imanaka T, Sakamoto A. Diquafosol ophthalmic solution for dry eye treatment. Advances in Therapy. 2012; 29(7), 579–589. doi:10.1007/s12325-012-0033-9
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2020 https://creativecommons.org/licenses/by-nc/4.0/
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
